Roncati L, Maiorana A
Urologia. 2010 Jan-Mar;77 Suppl 16:37-41.
Renal cell carcinoma is the sixth leading cause of death for cancer in industrialized countries and one third of patients has metastases at the time of diagnosis. The three most common histological types of renal cell carcinoma are: clear cell carcinoma (70-80%), papillary carcinoma (10-15%) and chromophobe cell carcinoma (5%). The location of metastases vary according to histotype: lung metastases are found in 53.6% of cases in patients with clear cell carcinoma, whereas in patients with papillary carcinoma or chromophobe cell carcinoma in 33.3% and 28.2% of cases, respectively. In contrast, chromophobe cell carcinoma is more often associated with liver metastases (33.3%), compared with clear cell carcinoma (9.7%) or papillary carcinoma (18%). Patients with renal cell carcinoma metastatic to a single organ have a better prognosis than patients with metastases in multiple organs and the overall survival of patients with localized lung metastases is similar to that of patients with exclusive bone metastases. The overall survival, therefore, is related more to the number of organs involved by metastasis rather than by the location of metastases. The widespread use of abdominal non-invasive diagnostic procedures, with an incidental finding of renal cell carcinomas still in a low stage of development, and the refinement of surgical techniques for resection of metastatic disease (metastasectomy) have led to only a slight improvement in overall survival in the last 30 years for the resistance of the tumor to common chemo-radiotherapy. Surgery remains the best therapeutic option and a rising in cutting-edge molecular therapies is strongly needed.
在工业化国家,肾细胞癌是癌症死亡的第六大主要原因,三分之一的患者在确诊时已有转移。肾细胞癌最常见的三种组织学类型为:透明细胞癌(70 - 80%)、乳头状癌(10 - 15%)和嫌色细胞癌(5%)。转移部位因组织学类型而异:透明细胞癌患者中53.6%有肺转移,而乳头状癌或嫌色细胞癌患者中分别为33.3%和28.2%有肺转移。相比之下,嫌色细胞癌更常伴有肝转移(33.3%),而透明细胞癌(9.7%)或乳头状癌(18%)则较少。转移至单个器官的肾细胞癌患者预后优于多器官转移患者,局限性肺转移患者的总生存率与单纯骨转移患者相似。因此,总生存率更多地与转移所累及的器官数量有关,而非转移的部位。腹部非侵入性诊断程序的广泛应用,偶然发现仍处于低发展阶段的肾细胞癌,以及转移性疾病切除手术技术(转移灶切除术)的完善,在过去30年中仅使总生存率略有提高,因为肿瘤对常见放化疗具有抗性。手术仍然是最佳治疗选择,迫切需要新兴的前沿分子疗法。